国家儿童健康与人类发展研究所新生儿研究网络中，极早产儿动脉导管未闭管理的长期变化趋势。
Secular Trends in Patent Ductus Arteriosus Management in Infants Born Preterm in the National Institute of Child Health and Human Development Neonatal Research Network.
机构信息
Department of Pediatrics, University of Wisconsin-Madison, Madison, WI.
Department of Pediatrics, McGovern Medical School, UTHealth Houston, Houston, TX.
出版信息
J Pediatr. 2024 Mar;266:113877. doi: 10.1016/j.jpeds.2023.113877. Epub 2023 Dec 20.
Abstract
We evaluated changes in patent ductus arteriosus (PDA) diagnosis and treatment from 2012 through 2021 in a network of US academic hospitals. PDA treatment decreased among infants born at 26-28 weeks but not among infants born at 22-25 weeks. Rates of indomethacin use and PDA ligation decreased while acetaminophen use and transcatheter PDA closure increased.
摘要
我们评估了 2012 年至 2021 年期间美国学术医院网络中动脉导管未闭（PDA）诊断和治疗的变化。26-28 周出生的婴儿中，PDA 治疗减少，但 22-25 周出生的婴儿中则没有。吲哚美辛和动脉导管结扎的使用率下降，而对乙酰氨基酚和经导管动脉导管未闭封堵的使用率增加。
相似文献
1
Secular Trends in Patent Ductus Arteriosus Management in Infants Born Preterm in the National Institute of Child Health and Human Development Neonatal Research Network.
J Pediatr. 2024 Mar;266:113877. doi: 10.1016/j.jpeds.2023.113877. Epub 2023 Dec 20.
2
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Cochrane Database Syst Rev. 2020 Jan 27;1(1):CD004213. doi: 10.1002/14651858.CD004213.pub5.
3
Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews.
Cochrane Database Syst Rev. 2023 Apr 11;4(4):CD013588. doi: 10.1002/14651858.CD013588.pub2.
4
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Cochrane Database Syst Rev. 2020 Jan 27;1(1):CD010061. doi: 10.1002/14651858.CD010061.pub4.
5
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.
Cochrane Database Syst Rev. 2008 Jan 23(1):CD003951. doi: 10.1002/14651858.CD003951.pub2.
6
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Cochrane Database Syst Rev. 2008 Jan 23(1):CD003481. doi: 10.1002/14651858.CD003481.pub3.
7
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.
Cochrane Database Syst Rev. 2003(3):CD003951. doi: 10.1002/14651858.CD003951.
8
[Transcatheter occlusion of patent ductus arteriosus in a preterm infant and review of literatures].
Zhonghua Er Ke Za Zhi. 2016 Jan;54(1):43-6. doi: 10.3760/cma.j.issn.0578-1310.2016.01.010.
9
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Cochrane Database Syst Rev. 2018 Sep 28;9(9):CD003481. doi: 10.1002/14651858.CD003481.pub7.
10
Efficacy and Costs of Three Pharmacotherapies for Patent Ductus Arteriosus Closure in Premature Infants.
Paediatr Drugs. 2022 Mar;24(2):93-102. doi: 10.1007/s40272-022-00495-1. Epub 2022 Mar 1.
引用本文的文献
1
Evaluating the efficacy and safety of milrinone for prevention of post-patent ductus arteriosus closure syndrome (the MIDAS trial) in extremely preterm infants: a multicentre, double-masked, randomised, placebo-controlled trial.
BMJ Open. 2025 Aug 26;15(8):e105018. doi: 10.1136/bmjopen-2025-105018.
2
Changes in cardiorespiratory status after transcatheter patent ductus arteriosus closure.
J Perinatol. 2025 Jun 16. doi: 10.1038/s41372-025-02329-7.
3
Respiratory Outcomes After Transcatheter vs Surgical Patent Ductus Arteriosus Closure in Preterm Infants.
JAMA Netw Open. 2025 Jun 2;8(6):e2513366. doi: 10.1001/jamanetworkopen.2025.13366.
4
Development and Validation of a Novel Deep Learning Model to Predict Pharmacologic Closure of Patent Ductus Arteriosus in Premature Infants.
J Am Soc Echocardiogr. 2025 Jul;38(7):624-632. doi: 10.1016/j.echo.2025.03.018. Epub 2025 Apr 11.
5
Impact of PDA Closure Methodology on Peri-procedural Opioid Utilization in Preterm Neonates, a Cross-Sectional Review in a Tertiary Pediatric Healthcare System.
Pediatr Cardiol. 2025 Apr 7. doi: 10.1007/s00246-025-03855-z.
6
Patent Ductus Arteriosus, Hydrocortisone, and Outcome among Infants Born Extremely Preterm: Secondary Analysis of the Hydrocortisone Trial.
J Pediatr. 2025 Jun;281:114535. doi: 10.1016/j.jpeds.2025.114535. Epub 2025 Mar 14.
7
Management of the patent ductus arteriosus among infants born at 23 to 32 weeks' gestation between 2011 to 2022: a report from in the Children's Hospitals Neonatal Consortium.
J Perinatol. 2025 Mar 15. doi: 10.1038/s41372-025-02257-6.
8
Beneficial vs harmful effects of pharmacological treatment of patent ductus arteriosus: A Bayesian meta-analysis.
Pediatr Res. 2025 Jan 15. doi: 10.1038/s41390-025-03820-9.
9
Patent Ductus Arteriosus Morphology Changes in Preterm Neonates Undergoing Transcatheter Device Closure.
Pediatr Cardiol. 2025 Jan 15. doi: 10.1007/s00246-025-03771-2.
10
Changes in Patent Ductus Arteriosus Management and Outcomes in Infants Born at 26-28 Weeks' Gestation.
J Pediatr. 2025 Apr;279:114456. doi: 10.1016/j.jpeds.2024.114456. Epub 2024 Dec 26.
本文引用的文献
1
Impact of Early Hemodynamic Screening on Extremely Preterm Outcomes in a High-Performance Center.
Am J Respir Crit Care Med. 2023 Aug 1;208(3):290-300. doi: 10.1164/rccm.202212-2291OC.
2
Acetaminophen for the patent ductus arteriosus: has safety been adequately demonstrated?
J Perinatol. 2023 Oct;43(10):1230-1237. doi: 10.1038/s41372-023-01697-2. Epub 2023 May 11.
3
Impact of early screening echocardiography and targeted PDA treatment on neonatal outcomes in "22-23" week and "24-26" infants.
Semin Perinatol. 2023 Mar;47(2):151721. doi: 10.1016/j.semperi.2023.151721. Epub 2023 Mar 5.
4
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
N Engl J Med. 2023 Mar 16;388(11):980-990. doi: 10.1056/NEJMoa2207418. Epub 2022 Dec 6.
5
Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants in the US, 2013-2018.
JAMA. 2022 Jan 18;327(3):248-263. doi: 10.1001/jama.2021.23580.
6
Variation of Patent Ductus Arteriosus Treatment in Very Low Birth Weight Infants.
Pediatrics. 2021 Nov;148(5). doi: 10.1542/peds.2021-052874. Epub 2021 Oct 21.
7
The evolution of cardiac point of care ultrasound for the neonatologist.
Eur J Pediatr. 2021 Dec;180(12):3565-3575. doi: 10.1007/s00431-021-04153-5. Epub 2021 Jun 14.
8
Changes in Patent Ductus Arteriosus Treatment Strategy and Respiratory Outcomes in Premature Infants.
J Pediatr. 2021 Aug;235:58-62. doi: 10.1016/j.jpeds.2021.04.030. Epub 2021 Apr 21.
9
Outcomes of Extremely Premature Infants Comparing Patent Ductus Arteriosus Management Approaches.
J Pediatr. 2021 Aug;235:49-57.e2. doi: 10.1016/j.jpeds.2021.04.014. Epub 2021 Apr 20.
10
Patent Ductus Arteriosus Clinical Trials: Lessons Learned and Future Directions.
Children (Basel). 2021 Jan 15;8(1):47. doi: 10.3390/children8010047.
Zotero 插件